QuantiFERON® – CMV
QuantiFERON® – CMV is a blood test that measures the immune response of CD8+ cells to CMV. The test is used to monitor people’s risks of developing CMV disease and can be used in connection with organ transplants to predict whether patients have an increased risk of developing CMV disease.
Human cytomegalovirus (CMV) is a herpes virus that infects between 50 and 85% of the adult population in the world. It is the most common virus that pregnant women can pass on to the unborn child, and which is responsible for 1 in 750 children being born with or developing disabilities as a result of the virus. CMV is an infectious pathogen associated with organ transplantation. In connection with transplantation, CMV is associated with increased disease and death.
QuantiFERON® – CMV has been developed to monitor individuals’ risks of developing CMV disease. In connection with organ transplants, the test can be used to predict whether patients have an increased risk of developing CMV disease and can thus support the clinician in the therapeutic treatment of these patients after the operation.
QuantiFERON® – CMV is a blood test that measures the immune response of CD8+ cells to CMV. The test requires the collection of three 1 mL blood samples in special antigen-coated sample tubes with subsequent ELISA analysis in the laboratory. The ELISA measures IFN gamma as a marker of a person’s ability to protect themselves against viral infection.
SSI Diagnostica distributes QuantiFERON® CMV in Denmark, Iceland, Norway and Sweden on behalf of CELLESTIS Inc. (a company in the Qiagen group), which has developed and manufactured the test.
- QFN CMV is the only commercial test for monitoring cellular immunity specific to CMV.
- QFN CMV is a simple test that only requires 3 x 1 mL blood samples with subsequent laboratory analysis.
- QFN CMV is a rapid test with results within 24 hours.
- QFN CMV can predict the likelihood of developing CMV disease and assist in the clinical and therapeutic treatment of transplant patients
Predict risk of new and recurrent CMV disease
Monitor transplant patient’s level of anti-CMV immunity
Determine both pre- and posttransplant CMV-risk stratification
Guide therapeutic decision making
Other interesting content
Looking for something else? You might be interested in this as well.
Please, reach out if you have questions, comments or requests.